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PPI Use and Increased Risk of Chronic Kidney Disease 
Abstract 
Background: Proton pump inhibitors (PPIs) are a class of gastric-acid reducing medications indicated for 
conditions including gastroesophageal reflux disease (GERD), peptic ulcer disease (PUD), Zollinger-Ellison 
syndrome, and erosive esophagitis. With 119 million PPI prescriptions filled in 2009, these are currently 
one of the most commonly prescribed classes of medication. The current list of known side effects for 
PPIs includes pneumonia, Clostridium difficile, hip fractures, acute interstitial nephritis (AIN), and 
malabsorption. The purpose of this review is to investigate if PPI use is also associated with an increased 
risk in developing chronic kidney disease (CKD) 
Methods: An exhaustive literature search using 3 search engines: Web of Science, MEDLINE-PubMed, and 
CINAHL databases. Key phrases used included: “proton pump inhibitors” and “chronic kidney disease”. 
Articles were assessed for quality using GRADE criteria. 
Results: Four articles met eligibility criteria and were included in this systematic review. All four were 
observational studies. Within each study, it was determined that those taking a PPI were at an increased 
risk in developing CKD versus those not taking one. Three of the 4 articles were downgraded to very low, 
and one was graded as low. 
Conclusion: PPI use appears to have an association with an increased risk in developing CKD. Providers 
should only prescribe PPIs when indicated and may want to try H2 blockers first to see if this helps the 
patient’s condition before progressing to a PPI. In order to determine a stronger association between PPI 
use and the development of CKD, further research needs to be conducted. 
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Abstract   
 
Background: Proton pump inhibitors (PPIs) are a class of gastric-acid 
reducing medications indicated for conditions including 
gastroesophageal reflux disease (GERD), peptic ulcer disease (PUD), 
Zollinger-Ellison syndrome, and erosive esophagitis. With 119 million 
PPI prescriptions filled in 2009, these are currently one of the most 
commonly prescribed classes of medication. The current list of known 
side effects for PPIs includes pneumonia, Clostridium difficile, hip 
fractures, acute interstitial nephritis (AIN), and malabsorption. The 
purpose of this review is to investigate if PPI use is also associated 
with an increased risk in developing chronic kidney disease (CKD). 
 
Methods:  An exhaustive literature search using 3 search engines: 
Web of Science, MEDLINE-PubMed, and CINAHL databases. Key 
phrases used included: “proton pump inhibitors” and “chronic kidney 
disease”. Articles were assessed for quality using GRADE criteria. 
 
Results:  Four articles met eligibility criteria and were included in this 
systematic review. All four were observational studies. Within each 
study, it was determined that those taking a PPI were at an increased 
risk in developing CKD versus those not taking one. Three of the 4 
articles were downgraded to very low, and one was graded as low.   
 
 - 3 - Revised 07Dec2009 
Conclusion:  PPI use appears to have an association with an 
increased risk in developing CKD. Providers should only prescribe PPIs 
when indicated and may want to try H2 blockers first to see if this 
helps the patient’s condition before progressing to a PPI. In order to 
determine a stronger association between PPI use and the 
development of CKD, further research needs to be conducted. 
 
Keywords:  Chronic kidney disease, proton pump inhibitor 
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 PPIs are one of the most commonly prescribed classes of medications with an 
approximately 113 million prescriptions filled globally each year.1 These gastric-acid 
reducing drugs are indicated for a wide array of disorders including GERD, peptic ulcer 
disease, erosive esophagitis, Helicobacter pylori, Zollinger-Ellison syndrome, and 
gastroduodenal ulcers associated with NSAID use. The increased use of PPIs has been 
fairly rapid. In 2009, the National Ambulatory Medical Care Survey found that the 
frequency of prescription PPI treatment went from less than 5 prescriptions per 1000 
GERD-related physician visits in 1995 to 43.9 prescriptions per 1000 GERD-related 
visits in 2006.2 This recent increase may partially be due to the fact that an estimated 25-
70% of PPI prescriptions have no appropriate indication.3    
 Similar to PPIs, histamine-2 (H2) blockers are a weaker gastric-acid reducing 
class of medication that are indicated for similar disorders including those listed above. 
Cost between PPIs and H2 blockers has been analyzed and H2 blockers are $11-$15 
cheaper per patient quarter.4  In addition to cost, the side effect profile for H2 blockers 
includes mild elevations in transaminases at high doses, confusion, and vitamin B12 
malabsorption versus PPIs which include hip fractures, Clostridium difficile infection, 
acute interstitial nephritis, community-acquired pneumonia, acute kidney injury (AKI),5-9 
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cardiovascular disease and death and hypomagnesia.10,11 Not currently included on this 
list is chronic kidney disease.  
 The incidence of CKD in developed countries has been rapidly growing as of late 
with a population prevalence now between 5-15%.12,13 CKD is associated with a 
substantially increased risk of comorbid complications and death, accounting for 
disproportionately large burden of healthcare and disability costs.14 While there is an 
association between PPI exposure and acute kidney injury (AKI), it is unclear whether 
PPI exposure is associated with an increased risk in developing CKD. With this increase 
in prevalence and the severe impact CKD has on healthcare, it would be greatly 
beneficial to find any unnecessary causes in order to begin reducing CKD prevalence. 
The objective of this review is to determine whether or not PPI exposure increases one’s 
risk for developing CKD when compared to those not exposed to PPIs.  
METHODS 
An exhaustive online search of medical literature was performed using Web of 
Science, MEDLINE-PubMed, and CINAHL databases. The keywords used during this 
search were “chronic kidney disease” and “proton pump inhibitors”. Eligibility criteria 
for the articles that were selected included those that were English language articles, not 
review articles, using human subjects, and published within the last 5 years. Inclusion 
criteria were defined as participants taking PPIs. Outcome variables were those that 
developed CKD after taking a PPI. CKD was defined differently depending on which 
article was being analyzed. Applicable articles were assessed for quality using the 
Grading of Recommendations, Assessment, Development, and Evaluation (GRADE).15 
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RESULTS 
 The exhaustive online search resulted in 143 articles to be reviewed.  Once 
screening these articles using the eligibility criteria, 4 articles16,17,18,19 remained that were 
relevant to the question at hand. These 4 studies were observational studies gathering data 
from a variety of populations. See Table 1. 
Arora et al 
 Published in 2016, this observational study16 attempted to identify if an 
association existed between PPI use and the development of CKD and death. The 
population being studied included those seen in Veterans Affairs Health Care Upstate 
New York network primary clinics between April 2001 and April 2008. PPI users were 
defined as those who filled out a PPI prescription and CKD was defined as an eGFR <60 
ml/min/1.73m2. Those with CKD prior to beginning their PPI were excluded from the 
CKD study in an attempt to establish a true association between PPI use and development 
of CKD. This resulted in a sample size for the mortality outcome of 99 269 patients and a 
sample size for the CKD outcome of 76 462 patients.16 
 Using a prospective logistic analysis, Arora et al16 were able to examine the 
relationship between PPI use and the primary outcomes of CKD onset and mortality 
while controlling for variables such as age, sex, race, GI and pre-PPI comorbidities.  
Once analyzing the data using multivariate analysis, the results showed a statistically 
significant increase in the rate of developing CKD as well as mortality for those taking 
PPIs as compared to those not taking PPIs.  The CKD outcome showed those in the PPI 
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group to have an odds ratio of 1.10 (95% CI: 1.05–1.16) and the mortality outcome 
showed those in the PPI group to have an odds ratio of 1.76 (95% CI: 1.68–1.84).16 
Another significant finding seen in these was an effect on the interaction of age 
and PPI use. Arora et al16 found those patients who began taking PPIs prior to the age of 
53 were at an increased risk of developing CKD when compared to those who began 
taking their PPI after the age of 53. Along those same lines, the results also revealed that 
patients who began taking their PPI prior to the age of 78 were at an increased risk for 
mortality versus those who began taking their PPI after the age of 78. 
Lazarus et al 
 Also published in 2016, this observational study17 was conducted searching for an 
association between PPI use and developing CKD. Participants were gathered from the 
Atherosclerosis Risk in Communities (ARIC) study, a prospective cohort study from 4 
US cities including: Forsyth, North Carolina; Jackson, Mississippi; suburban 
Minneapolis; and Washington county, Maryland. Data collection began in 1987 and 
concluded in 2011 with participants performing follow up visits periodically. Excluding 
participants with missing data points for eGFR, ratio of urinary albumin to creatinine, or 
participants with an eGFR <60 ml/min/1.73m2 prior to taking their PPI, the sample size 
Lazarus et al17 were left to study was 10 482. In the ARIC study, CKD was defined by 
diagnostic codes that indicated CKD at hospital discharge. They also took note of those 
taking H2 blockers to compare this group to those taking PPIs. They also conducted a 
replication cohort study for 248 751 participants gathering data from 1997 – 2014 from 
the Geisinger Health System. The major difference between this replication study and the 
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ARIC study was that for the replication study, CKD was defined as an eGFR <60 
ml/min/1.73m2.17 
 Using Cox proportional hazards regression to estimate hazard ratios, the results 
revealed that at baseline in the ARIC study, PPI users had a hazard ratio of 1.45 (95% CI, 
1.11-1.90) meaning they were 1.45 times more likely to develop CKD versus nonusers.  
When taking into account other possible confounders including demographics, 
socioeconomic status, clinical measurements, prevalent comorbidities, and concomitant 
use of other medications (aHR, 1.50; 95% CI, 1.14-1.96)  as well as time-varying ever-
use variable (aHR, 1.35; CI 95%, 1.17-1.55), the hazard ratios showed similar findings. 
The data also showed that the 10-year risk for developing CKD for those using PPIs was 
11.8% versus nonusers which was 8.5%, an absolute risk difference of 3.3%. In the 
replication cohort study, PPI users were also at an increased risk in developing CKD at 
baseline (HR, 1.20; 95% CI, 1.15-1.26), when adjusted for possible confounders (aHR, 
1.17; 95% CI, 1.12-1.23), and adjusted using time-varying ever-use variable (aHR, 1.22; 
95% CI, 1.19-1.25).  The replication study also found that PPI users who used twice daily 
had a HR of 1.46 (95% CI, 1.28-1.67) versus a hazard ratio of 1.15 (95% CI, 1.09-1.21)  
seen in those who used once daily.  Finally, Lazarus et al found that those taking H2 
blockers and not taking PPIs were not at an increased risk in developing CKD.17 
Klatte et al 
 This observational study18 was conducted to compare new PPI users versus new 
H2 blocker users with the primary outcome being CKD progression. CKD progression 
was defined as doubling of serum creatinine or as >30% decline in eGFR. Klatte et al18 
retrieved data on patients >18 years old beginning a PPI or H2 blocker from the 
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Stockholm creatinine measurements healthcare utilization cohort which includes all 
patients in this region who had received a creatinine reading in ambulatory or hospital 
care from 2006-2011. Exclusion criteria included those with an eGFR <15 
ml/min/1.73m2 or those receiving renal replacement therapy.  Using these criteria, the 
sample size for new H2 blocker users was 9578 participants and the sample size for new 
PPI users was 105 305 participants.18   
 Using Cox regressions, the results show the new PPI users have a hazard ratio of 
1.26 (95% CI; 1.05-1.51) for the doubling of serum creatinine and a hazard ratio of 1.26 
(95% CI; 1.16-1.36) for experiencing a >30% decline in eGFR versus new H2 blocker 
users. Additionally, Klatte et al discovered that cumulative PPI use was also related to an 
increased risk for the doubling of serum creatinine and experiencing a >30% decrease in 
eGFR. This was not seen when analyzing the new H2 blocker user group.18 
Xie et al 
 This observational study19 took a similar approach to the Klatte et al study in 
analyzing 2 groups: new PPI users and new H2 blocker users. This study was interested 
in determining if PPI use had an association with developing CKD, CKD progression, 
and end-stage renal disease (ESRD) for those who did not have preexisting kidney 
disease prior to the study as defined by an eGFR >60 ml/min/1.73m2. The participants 
were gathered from the United States Department of Veterans Affairs databases. This 
resulted a new PPI user sample size of 173 321 participants and a new H2 blocker sample 
size of 20 270.19 
 Results from this study first showed that of the 173 321 new PPI users, 48 171 
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saw their eGFR decrease to eGFR >60 ml/min/1.73m2 (27.8%) versus 4429 of the 20 270 
new H2 blockers (21.9%). The Cox survival models hazard ratio for eGFR >60 
ml/min/1.73m2 which takes into account demographic, eGFR, clinical comorbid 
conditions, and other health characteristics, the hazard ratio is 1.22 (95% CI, 1.18 to 1.26 
) for the new PPI user group. The results also analyzed development of CKD which was 
defined by diagnostic codes that indicated CKD at hospital discharge or death. What they 
found was that 26 193 new PPI users developed CKD (15.1%) whereas 2234 (11.0%) of 
the new H2 blocker participants developed CKD.19 
 Taking the results even further, it was found using adjusted survival models that 
PPI users risk of doubling their serum creatinine and experiencing an eGFR decline of 
>30% was much higher than those taking H2 blockers. They found that the number 
needed to harm for those in the new H2 blocker group was 175 versus the new PPI user 
group which was 61. Xie et al also looked at the development of ESRD and in using 
adjusted survival models, they found an increased risk for those taking PPIs with a hazard 
ratio of 1.96 (95% CI, 1.21 to 3.18).19 
DISCUSSION 
 As mentioned previously, both PPI use as well as CKD have seen relatively large 
increases in prevalence recently. With PPIs being one of the most commonly prescribed 
medications in the United States, this review was conducted in an attempt to discover if 
an association exists between PPI use and an increased risk in developing CKD. Keeping 
in mind that an estimated 25-70% of PPI prescriptions have no appropriate indication,3 
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this may be an area of medicine that providers can reduce the number of prescriptions 
and thus reduce the number of side effects. If an association can be found, providers 
could then practice accordingly by reducing unnecessary PPI prescriptions, ultimately 
reducing the number of patients with what may be unnecessary CKD. 
 Once compiling all of the data and results from these 4 studies,16,17,18,19 there 
appeared to be some fairly consistent findings. Although there were minor differences in 
the way CKD was defined between studies, it was clear that those who did not have CKD 
when starting a new prescription of their PPI were then at an increased risk for 
developing CKD once taking their PPI. Klatte et al18 references the studies conducted by 
Arora et al,16 Lazarus et al,17 and Xie et al19 stating that their results are remarkably 
similar to these other studies. This consistency makes it hard to ignore that there quite 
possibly is an association between PPI use and risk in developing CKD.  
Arora et al16 shares a few theories that may explain this association. First 
discussed is the possibility that patients taking a PPI suffer from the known side effect 
AIN but do not realize it. This left untreated may lead to irreversible interstitial fibrosis 
which could then eventually lead to CKD. They also mention that another known side 
effect of PPIs, hypomagnesia, can lead to endothelial cell dysfunction and chronic 
interstitial nephritis which may play a role in the development of CKD.16 Although these 
are nothing more than theories and more studies would need to be conducted to determine 
absolutes, it does appear that an association exists between PPI use and an increased risk 
in developing CKD. 
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 Also consistent were the results seen when specifically comparing PPI users to H2 
blocker users. The results showed that PPI users were at an increased risk for developing 
CKD,17,18,19 doubling of creatinine and decreasing eGFR >30%,18 and developing 
ESRD,18 versus the H2 blocker users who had no increased risk in developing 
CKD.17,18,19 With both drugs being used for similar indications, this finding may suggest 
that more providers may consider beginning patients on a trial of an H2 blocker before 
jumping to a PPI. This is not to suggest there is no place for PPIs in current practice; 
however, this is simply pointing out that in many cases, an H2 blocker trial may be worth 
trying before resorting to a PPI.  
 Some of these studies also looked at PPIs association with an increased risk in 
developing CKD in relation to age16 or cumulative exposure.18,19 Arora et al16 focused 
more on the age aspect and found that patients beginning a PPI <53 years of age were at a 
significantly higher risk in developing CKD versus those over 53. Klatte et18 al and Xie et 
al19 found that as cumulative exposure to a PPI increased, so did the patient’s risk in 
developing CKD.  These findings are significant in showing that younger patients who 
will need to be treated chronically with acid suppressants may be significantly increasing 
their risk for developing CKD versus an elderly patient or someone who will only need 
short term treatment.  
 Three of the 4 studies16,18,19 were deemed very low quality evidence using the 
GRADE guidelines (Table 1). Simply the fact that all 4 are observational studies means 
no causality can be drawn from this review. In addition to this, 2 of the studies16,17 do not 
show clearly how long their patients were exposed to PPIs. This is an important piece of 
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information that should be shown in the data. While Lazarus et al17 did find that twice-
daily PPI dosing increased one’s risk more so than once-daily PPI dosing, the duration of 
PPI use was not explained or shown clearly. As for Xie et al,19 this study was 
downgraded due to the fact that the sample size being studied was not representative, 
consisting largely of only elderly, white males. That being said, with the 4 studies16,17,18,19 
showing extremely consistent findings, it does suggest that there could be association that 
exists between PPI use and an increased risk for developing CKD. 
 
CONCLUSION 
 Evidence for an association between PPI use and an increased risk in developing 
CKD is suggestive. Since all 4 are observational studies, it is not possible to confirm 
causality; however, these consistent findings do suggest an association may exist. The 
studies also suggest that those taking H2 blockers are not at an increased risk for 
developing CKD. Considering H2 blockers are prescribed for the same indications as 
PPIs, this finding may cause providers to begin putting their patients on an H2 blocker 
first to see if this treats their indicated disease before beginning a PPI. Results also show 
that those beginning a PPI less than 53 years old and those with more cumulative 
exposure to PPIs are at an increased risk for developing CKD. This may cause providers 
to have a higher threshold in prescribing PPIs to younger patients or those needing 
chronic treatment. 
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Limitations Indirectness Inconsistency Imprecision 
Publication 
bias 
Arora et al16 Observational 
Study 






Seriousa Not Serious Not Serious Not Serious Unlikely N/A Very 
Low 




Not Serious Not Serious Not Serious Unlikely N/A Low 
Xie et al19 Observational 
Study 
Seriousb Not Serious Not Serious Not Serious Unlikely N/A Very 
Low 
a Length of PPI use was not indicated clearly.  
b The population was not representative, focused primarily on elderly white males. 
 
 
 
 
 
 
 
 
